Taiwan-based startup Point Robotics MedTech Inc. has received 510(k) clearance from the US Food and Drug Administration ...
Thermo Fisher Scientific has partnered with the Taiwan Precision Medicine Initiative (TPMI) to advance the next phase of...
Bora Pharmaceutical Laboratories Inc. (Zhunan), a division of Bora Pharmaceuticals has partnered with TaiRx, Inc., a Tai...
Taiwan-based Charsire Biotechnology Corp has successfully developed a revolutionary new drug (BAC) for Alzheimer's disea...
Brain Navi, a surgical robot manufacturer in Taiwan, has announced a strategic partnership with distributor, Medtreq Med...
Medical Fair Asia 2022 brought 14th International Exhibition on Hospital, Diagnostic, Pharmaceutical, Medical & Reha...
Digital health startup AESOP Technology has raised a $2.95 million series pre-A round to address the growing medic...
South Korea-based startup Lunit has received commercial approval in Taiwan for Lunit INSIGHT MMG, the company's artifici...
Taiwan Excellence will be participating for the first time at the Medical Fair Asia 2022, to be held on-site at Marina B...
China's Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmace...
NaoTrac, the CE-certified neurosurgical navigation robot by Taiwanese startup Brain Navi, has achieved approval from&nbs...
With its impressive achievements, Molsentech (Molecular Sensoring Technology Co., Ltd.) got selected by the TTA Global C...
Taiwanese startup CancerFree Biotech has developed a breakthrough for patients with stage 2 solid tumour to shorten...
TFBS Bioscience Inc., the leading GMP viral vector contract development and manufacturing organization in the Asia-Pacif...
Taiwan's Flat Medical, a MedTech company specializing in safety solutions for anesthesia and critical care procedures, h...
Taiwan-based startup Health2Sync is signing a Memorandum of Understanding (MoU) with AstraZeneca Taiwan to provide its f...
Amaran Biotechnology Inc., a subsidiary of Taiwan's OBI Pharma Inc., has completed the construction of it...
OBI Pharma, a Taiwan biopharma company announced discontinuation of the Phase 1/2 Study for OBI 888, a Globo H antibody,...
